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Abstract
Introduction: Many HIV-positive individuals in Africa have advanced disease when initiating antiretroviral therapy (ART) so
have high risks of opportunistic infections and death. The REALITY trial found that an enhanced-prophylaxis package including
fluconazole reduced mortality by 27% in individuals starting ART with CD4 <100 cells/mm3. We investigated the cost-effec-
tiveness of this enhanced-prophylaxis package versus other strategies, including using cryptococcal antigen (CrAg) testing, in
individuals with CD4 <200 cells/mm3 or <100 cells/mm3 at ART initiation and all individuals regardless of CD4 count.
Methods: The REALITY trial enrolled from June 2013 to April 2015. A decision-analytic model was developed to estimate
the cost-effectiveness of six management strategies in individuals initiating ART in the REALITY trial countries. Strategies
included standard-prophylaxis, enhanced-prophylaxis, standard-prophylaxis with fluconazole; and three CrAg testing strategies,
the first stratifying individuals to enhanced-prophylaxis (CrAg-positive) or standard-prophylaxis (CrAg-negative), the second to
enhanced-prophylaxis (CrAg-positive) or enhanced-prophylaxis without fluconazole (CrAg-negative) and the third to standard-
prophylaxis with fluconazole (CrAg-positive) or without fluconazole (CrAg-negative). The model estimated costs, life-years and
quality-adjusted life-years (QALY) over 48 weeks using three competing mortality risks: cryptococcal meningitis; tuberculosis,
serious bacterial infection or other known cause; and unknown cause.
Results: Enhanced-prophylaxis was cost-effective at cost-effectiveness thresholds of US$300 and US$500 per QALY with an
incremental cost-effectiveness ratio (ICER) of US$157 per QALY in the CD4 <200 cells/mm3 population providing enhanced-
prophylaxis components are sourced at lowest available prices. The ICER reduced in more severely immunosuppressed individ-
uals (US$113 per QALY in the CD4 <100 cells/mm3 population) and increased in all individuals regardless of CD4 count (US
$722 per QALY). Results were sensitive to prices of the enhanced-prophylaxis components. Enhanced-prophylaxis was more
effective and less costly than all CrAg testing strategies as enhanced-prophylaxis still conveyed health gains in CrAg-negative
patients and savings from targeting prophylaxis based on CrAg status did not compensate for costs of CrAg testing. CrAg test-
ing strategies did not become cost-effective unless the price of CrAg testing fell below US$2.30.
Conclusions: The REALITY enhanced-prophylaxis package in individuals with advanced HIV starting ART reduces morbidity
and mortality, is practical to administer and is cost-effective. Efforts should continue to ensure that components are accessed
at lowest available prices.
Keywords: HIV; prophylaxis; fluconazole; late-presenters; cost-effectiveness
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1 | INTRODUCTION
In low- and middle-income settings, more than a third of
HIV-positive individuals starting antiretroviral therapy (ART)
present with advanced disease (CD4 ≤ 200 cells/mm3); over
half of these have CD4 ≤ 100 cells/mm3 [1,2]. Such “late-
presenters” have increased risks of opportunistic infections
and death shortly after starting ART [1,3], particularly from
severe bacterial infections [4], tuberculosis [5–7] and crypto-
coccal meningitis [8,9]. Prophylaxis, immediately before or
concomitantly with ART, can prevent infections and reduce
mortality [10].
The REALITY trial assessed the effectiveness of an
“enhanced-prophylaxis package” for HIV-positive adults,
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adolescents and children greater than five years initiating ART
with CD4 <100 cells/mm3. The package included a daily fixed-
dose combination tablet (FDC) of trimethoprim-sulfmethoxa-
zole, isoniazid and pyridoxine, 12 weeks’ fluconazole 100 mg
daily, five days’ azithromycin 500 mg daily and a single dose
of albendazole [10]. Patients with clinical evidence of oppor-
tunistic infections at enrolment (e.g. cryptococcal meningitis)
received infection-specific treatment; cryptococcal antigen
(CrAg) testing was not routinely performed. The enhanced-
prophylaxis package reduced all-cause mortality by 27% (from
12.2% to 8.9%) over 24 weeks, significantly reducing crypto-
coccal deaths and deaths from unknown causes.
The 2017 Guideline Development Group at the World
Health Organization (WHO) expressed concerns about the
universal use of fluconazole in this population relating to
costs, the potential for anti-fungal resistance, and foetal safety
among women of childbearing age. Hence, they recommended
a reduced package of targeted prophylaxis including flucona-
zole as pre-emptive treatment (not prophylaxis) only in indi-
viduals with CD4 <100 cells/mm3 who test positive for CrAg,
consistent with WHO guidelines for cryptococcal meningitis at
the time [11]. Updated WHO guidance in 2018 recommended
unrestricted fluconazole primary prophylaxis for individuals
with CD4 <100 cells/mm3 (with consideration if CD4
<200 cells/mm3) where access to CrAg testing is limited, or
where prolonged delays in receiving test results might occur,
for example, ART initiation at lower level facilities (conditional
recommendation; moderate-certainty evidence).
We consider the cost-effectiveness of universal enhanced-
prophylaxis versus other strategies including restricting flucona-
zole (as pre-emptive treatment) to CrAg-positive individuals, to
identify the optimal strategy in individuals presenting with
advanced HIV, and all newly presenting individuals, in the REA-
LITY trial countries (Zimbabwe, Uganda, Malawi and Kenya).
2 | METHODS
A decision-analytic model was developed to estimate costs
and health outcomes of different strategies. Costs were esti-
mated from a healthcare system perspective using country-
specific unit costs (price year 2016 US$). Health outcomes
were expressed as life-years and quality-adjusted life-years
(QALYs) (a generic health measure capturing both quantity
and quality of life; one QALY represents a year in perfect
health). A 48-week time horizon was used, reflecting trial fol-
low-up [10]. Cost-effectiveness was assessed using incremen-
tal cost-effectiveness ratios (ICERs) and incremental net
health benefits. ICERs represent the cost per additional unit
of benefit of a strategy versus the next best strategy, where
extendedly dominated strategies (i.e. those which cost more
per additional unit of benefit than the next most effective
strategy) are excluded from comparison. Incremental net
health benefits (measured in QALYs) reflect the difference
between the health generated with the strategy (vs. a refer-
ence strategy) and the health which would have been gener-
ated elsewhere if the required resources were used for
alternative purposes (e.g. health generated by other treat-
ments). Cost-effectiveness thresholds represent the marginal
productivity of the healthcare system (i.e. how much health
would be generated elsewhere for a given resource), and we
here considered commonly used threshold values of US$100,
US$300 and US$500/QALY [12]. At a given threshold, the
strategy with the highest ICER below that threshold or with
the highest incremental net health benefit is cost-effective.
2.1 | Patient population
Three populations of previously untreated HIV-positive adults/
adolescents with advanced HIV disease without evidence of
clinical opportunistic infection (including Cryptococcus) at pre-
sentation in sub-Saharan Africa were considered, with: (i) CD4
<200 cells/mm3; (ii) CD4 <100 cells/mm3 (REALITY inclusion
criteria; 40 (2.2%) children aged 5-12 years also recruited);
and (iii) all individuals, regardless of CD4 count.
2.2 | Management strategies
Six alternative management strategies over the first 12 weeks
on ART were considered:
Strategy-1: Standard-prophylaxis: 12 weeks’ 160 mg
trimethoprim/800 mg sulfamethoxazole daily (REALITY
control group).
Strategy-2: Enhanced-prophylaxis: 12 weeks’ FDC of
trimethoprim-sulfmethoxazole, isoniazid (300 mg) and pyri-
doxine (25 mg) plus fluconazole (100 mg daily). Addition-
ally, at ART initiation, single-dose albendazole (400 mg) and
five days’ azithromycin (500 mg daily) (REALITY interven-
tion group).
Strategy-3: 12 weeks’ trimethoprim/sulfamethoxazole and
fluconazole (Strategy-2 excluding isoniazid/pyridoxine).
Strategy-4: First CrAg testing strategy: CrAg test at pre-
sentation, with CrAg-positives receiving full enhanced-pro-
phylaxis (12 weeks’ FDC plus fluconazole (100 mg daily),
single-dose albendazole and five days azithromycin (Strat-
egy-2)) and CrAg-negatives receiving standard-prophylaxis
(12 weeks’ trimethoprim/sulfamethoxazole (Strategy-1)).
Strategy-5: Second CrAg testing strategy: CrAg test at pre-
sentation, with CrAg-positives receiving full enhanced-pro-
phylaxis (12 weeks’ FDC plus fluconazole (100 mg daily),
single-dose albendazole and five days azithromycin (Strat-
egy-2)) and CrAg-negatives receiving 12 weeks’ FDC, sin-
gle-dose albendazole and five days azithromycin (Strategy-
2 excluding fluconazole).
Strategy-6: Third CrAg testing strategy: CrAg test at pre-
sentation, with CrAg-positives receiving 12 weeks’
trimethoprim/sulfamethoxazole plus fluconazole (100 mg
daily) (Strategy-3) and CrAg-negatives receiving 12 weeks’
trimethoprim/sulfamethoxazole (Strategy-1).
For all strategies, in countries where isoniazid prophylaxis
became standard-of–care during the trial (Uganda, Zimbabwe,
Kenya), from 12 weeks onwards individuals in the trial
received FDC, and in countries where isoniazid prophylaxis
was not standard-of-care during the trial (Malawi), from
12 weeks onwards individuals received trimethoprim-sul-
famethoxazole alone. Event rates were very low after
12 weeks on ART [13], so differences in whether or not isoni-
azid/pyridoxine was part of standard-prophylaxis after
12 weeks would have minimal effect. Full details of the strate-
gies are provided in Table A1 in the Appendix.
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2.3 | Decision-analytic model
The model is a Markov cohort model with one alive state and
mortality from three competing risks: cryptococcal meningitis;
tuberculosis, serious bacterial infection or other known cause;
and unknown cause (Appendix Figure A1). The model has a
one-week cycle length and considers 48 cycles. During each
one-week cycle, individuals can die from one of the three com-
peting risks or survive and incur costs based on the six
resource categories (initial CrAg test, prophylaxis, ART, other
concomitant medications, clinic visits and hospitalizations
(cryptococcus-specific and other)) and accrue life-years and
QALYs based on their health-related quality-of-life (HRQoL)
weight. Costs, life-years and QALYs are then aggregated over
the 48 weeks to estimate totals over the time period. The
model was developed in Microsoft Excel.
The decision-analytic model was evaluated separately over
10 cell/mm3 subgroups of baseline CD4 (i.e. 0-10, 10-
20 cells/mm3, etc) as the relationships with CD4 are non-lin-
ear and disaggregating into subgroups results in more accu-
rate estimations. Estimates then weighted the 10-cell
subgroup results by the proportions in each subgroup within
the population of interest. Individuals with CD4 >200 cells/
mm3 were assumed to incur costs of prophylaxis and CrAg
testing but receive no mortality benefit or impacts on other
cost categories from prophylaxis. CD4 testing costs were not
included but the value of CD4 testing for stratifying individu-
als to different strategies was considered as a scenario analy-
sis. Table 1 indicates the sources of model inputs.
2.4 | Data
The main primary data source was REALITY which enrolled
individuals from June 2013 through April 2015 [10]. These data
informed participant characteristics (including proportions in
CD4 subgroups <100 cells/mm3) (Appendix Tables A2 and A3),
and were used to estimate cause-specific mortality hazards
over time, costs incurred and HRQoL weights, using regression
analyses. Data from retrospective CrAg testing of stored sam-
ples from REALITY were also used [14]. The DART trial [15]
informed proportions in CD4 subgroups between 100 and
200 cells/mm3. A South African study informed the proportion
of individuals presenting for ARTwith CD4 0-100, 100-200 and
200+ cells/mm3 (Appendix Table A3) [1].
2.5 | Ethics and consent
The REALITY trial was approved by ethics committees in Zim-
babwe, Uganda, Malawi, Kenya and the United Kingdom. Adult
patients and guardians provided written informed consent
with older children providing additional assent according to
national guidelines.
2.6 | Analysis
2.6.1 | Survival
Cause-specific hazards for death from (i) cryptococcal menin-
gitis, (ii) tuberculosis, serious bacterial infection or other
known cause and (iii) unknown cause (Appendix Figure A1)
were estimated from REALITY using competing risk piecewise
exponential models (intervals 0-8, 8-24 and 24-48 weeks
reflecting changing hazards over time). Covariates considered
for inclusion were: baseline CD4 (either absolute or log-trans-
formed), randomized treatment (standard-prophylaxis vs.
enhanced-prophylaxis), baseline CrAg status, and an interac-
tion between treatment and CrAg status. Covariates were
included based on multivariable p < 0.1. Given the aim to
extrapolate relationships to CD4 >100 cells/mm3, the choice
of CD4 scale was also informed by DART data (baseline CD4
0-200 cells/mm3) [15]. On this basis, absolute scale CD4
parameterization was used for all analyses.
2.6.2 | Costs and resource use
Prophylaxis costs were based on the mean number of
recorded prescriptions in REALITY and the minimum price for
each drug across countries provided by pharmacies involved
in REALITY (Table 2). The CrAg test cost was US$5.66 based
on costs within REALITY (including discounted test, consum-
ables and labour) [14]. All inferences were based on REALITY
data with unit costs taken from published sources
(Appendix Table A4) [16,17]. ART and clinic visits costs were
Table 1. Model inputs
Model inputs Full details Main source
Patient level covariates Table A1 REALITY trial [10]
Baseline CD4 distribution Table A2 REALITY trial [10]
DART trial [15]
Carmona et al. [1]
Cause specific mortalitya Table A4 REALITY trial [10]
HRQoL Table A7 REALITY trial [10]
Jelsma et al. [19]
Prophylaxis drug unit costs Table 2 Pharmacies involved in
REALITY trial
Other unit costs Table A3 Economic Anlysis and
Evaluation Team,
WHO [16]
International drug price
indicator guide [17]
Clinic visit costs Table A5 REALITY trial [10]
Economic Anlysis and
Evaluation Team,
WHO [16]
ART costs Table A5 REALITY trial [10]
International drug price
indicator guide [17]
Hospitalization costs
(cryptococcal and other)
Table A6 REALITY trial [10]
Economic Anlysis and
Evaluation Team,
WHO [16]
Concomitant drug costs Table A6 REALITY trial [10]
International drug price
indicator guide [17]
ART, antiretroviral therapy; HRQoL, health-related quality-of-life.
a
DART trial used to inform suitability of extrapolation of results above
CD4 100 cells/mm3.
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estimated using a panel data approach with weekly waves (48
waves). For concomitant medications, cryptococcal-specific
hospitalizations and other hospitalizations, a two-stage regres-
sion approach was used; firstly (panel data) estimating the
probability of a resource being used in any given week, and
secondly regression estimating the mean weekly cost given
the resource was used. Covariates considered for inclusion
were randomized prophylaxis (enhanced-prophylaxis vs. stan-
dard-prophylaxis), baseline CD4, CrAg status, CrAg and treat-
ment interaction, age, sex, time since ART initiation and three
time to death indicators (subsequently dying within 0-4, 5-8
and 9-12 weeks) reflecting potential resource implications of
being close to death. Covariates were included if multivariable
p < 0.1.
2.6.3 | Health-Related Quality-of-Life
HRQoL was measured within REALITY using the EQ-5D-3L tool
[18], a generic preference-based measure of health encompass-
ing five dimensions, at baseline, 2, 4, 8, 12, 18, 24, 36 and
48 weeks. HRQoL weights were derived from EQ-5D-3L
responses using a published tariff from Zimbabwe [19], with 1
representing perfect health and 0 death. HRQoL weights were
modelled using linear random effects regression with the fol-
lowing covariates: randomized prophylaxis, baseline CD4, age,
sex, time since ART initiation and time to death indicators as
above. Covariates were retained if multivariable p < 0.1. For an
alternative scenario, baseline CD4 was replaced with baseline
HRQoL score. Another scenario imposed a maximum HRQoL
score of 0.9 for individuals in full health (to reflect the range of
values in the original Zimbabwean study). QALYs were esti-
mated from time alive and the HRQoL weights.
2.6.4 | Incorporating treatment effects
The decision model includes prophylaxis strategies that were
not investigated within REALITY, specifically removing flucona-
zole from enhanced-prophylaxis and adding fluconazole to
standard-prophylaxis. This requires assumptions about effects
of fluconazole and other enhanced-prophylaxis components.
We assumed that differences between enhanced-prophylaxis
and standard-prophylaxis on cryptococcal meningitis (mortality
and hospitalization) were attributed to fluconazole only. Con-
versely, any effects of enhanced-prophylaxis on other mortality
causes or resource use were attributed to other parts of the
package (Table 3).
2.6.5 | Probabilistic and scenario analyses
The probability of a strategy being cost-effective was evaluated
using probabilistic sensitivity analysis for the base-case, with
uncertainty in each of the equations used to populate the model
incorporated assuming multivariate normality of the coefficients
and propagated through the model using Monte Carlo simula-
tion to determine overall decision uncertainty [20]. Scenario
analyses included alternative (including country-specific) costs
for prophylaxis drugs, US$12 annual FDC cost (based on ceiling
price agreement and assumption of 50% reduction for bulk pur-
chasing [21]) and fluconazole cost at 200 mg dose (with no
change in efficacy). We also considered an alternate model for
cryptococcal mortality that included an interaction between
enhanced-prophylaxis and CrAg status. A final scenario consid-
ered WHO-recommended fluconazole pre-emptive treatment
for CrAg-positive individuals in CrAg testing strategies (two
weeks’ 800 mg daily, then eight weeks’ 400 mg). There is no
direct evidence on the effectiveness of this regimen (e.g. in the
REMSTART trial [22] it was assessed in combination with
adherence support and the effects of pre-emptive fluconazole
therefore cannot be isolated). We here assumed this regimen to
remove all risk of cryptococcal mortality and hospitalization,
which is an optimistic scenario given conflicting evidence on the
impact on mortality [22,23].
Finally, we determined the maximum price of CrAg tests at
which a CrAg-testing strategy would be cost-effective and the
maximum price of CD4 (to assign individuals to different
strategies).
3 | RESULTS
We first present the results of the statistical analyses (on sur-
vival, costs and resource use and HRQoL) performed using
Table 2. Prophylaxis drug costs (2016 US$)
Costs Zimbabwe Uganda Malawi Kenya Cheapesta
Albendazole (400 mg) 1.000 0.100 0.290 0.040 0.040
Azithromycin (500 mg) 4.470 0.264 0.562 0.156 0.156
Fluconazole (100 mg) 0.086 0.051 0.330 0.031 0.031
FDCb 0.038 0.057 0.026 0.054 0.026
Co-trimoxazole (800/160 mg) 0.009 0.009 0.009 0.009 0.009
Isoniazid and pyridoxine (300/25 mg) 0.029 0.048 0.017 0.045 0.017
48-week protocol prophylaxis medication costs
Enhanced-prophylaxis 43.34 24.86 39.56 21.57 12.16
Standard-prophylaxis 10.33 15.12 3.02 14.36 6.70
Costs based on those reported by pharmacists involved in the REALITY trial.
FDC, fixed-dose combination.
a
Base-case prophylaxis drug costs: the lowest value taken across all country-specific prophylaxis drug costs;
b
Fixed dose combination of trimetho-
prim-sulfmethoxazole (800/160 mg), isoniazid (300 mg) and pyridoxine (25 mg).
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the REALITY trial data, which will reflect outcomes of the tri-
alled interventions, Strategy-2 and Strategy-1, in patients with
CD4 <100. As described in the methods section, the results
of these analyses were used to populate the decision model
to evaluate the cost-effectiveness of the six strategies.
3.1 | Statistical analysis
3.1.1 | Survival
Enhanced-prophylaxis (REALITY Intervention Group, Strategy-
2) significantly reduced cryptococcal and unknown mortality in
relation to standard-prophylaxis (REALITY Intervention Group,
Strategy-1): hazard ratios (HR) 0.30 [95% CI: 0.10, 0.92;
p = 0.04] and 0.62 [0.40, 0.95; p = 0.03] respectively
(Appendix Table A5). Although enhanced-prophylaxis reduced
morbidity, there was no evidence of effect on mortality from
tuberculosis, serious bacterial infection or other known causes.
CrAg-positivity was only associated with increased cryptococ-
cal mortality (HR = 42.62 [12.18, 149.22; p < 0.001]). Higher
CD4 was associated with a decreased hazard for all three
mortality causes. Mortality hazards decreased markedly over
time after ART initiation. Estimated and observed competing
risk survival curves were similar (Appendix Figure A2).
3.1.2 | Costs and resource use
Clinic visit costs were associated with age, country and time
since ART initiation, and ART costs with age and country but
not CD4 or CrAg status (Appendix Table A6). Enhanced-pro-
phylaxis reduced the probability of cryptococcal hospitaliza-
tions and other hospitalizations in relation to standard-
prophylaxis (odds ratio (OR) 0.56 [0.33, 0.94; p = 0.28] and
0.84 [0.67, 1.06; p = 0.14] respectively), while CrAg-positivity
was associated with increased probability of cryptococcal
hospitalization (OR = 99.22 [44.65, 220.48; p < 0.001]) but
reduced probability of other hospitalizations (OR = 0.44
[0.25, 0.76; p = 0.003]) (Appendix Table A7). Enhanced-pro-
phylaxis and CrAg-positivity did not impact the probability of
using concomitant drugs in any given cycle but did reduce
and increase costs respectively if an individual did use con-
comitant drugs in that cycle (weekly costs difference of
$−0.16 [−0.34, 0.02] and $1.20 [0.87, 1.53] respectively).
The probability of each incurred cost increased in the weeks
prior to death.
3.1.3 | HRQoL weights
Enhanced-prophylaxis was associated with higher HRQoL
weights than standard-prophylaxis although this was not sta-
tistically significant (incremental HRQoL weight 0.007
[−0.002, 0.016; p = 0.12]) (Appendix Table A8). Time since
ART initiation was also associated with higher HRQoL weights
(i.e. HRQoL improved with time), and in the weeks prior to
death HRQoL weights decreased.
3.2 | Base-case cost-effectiveness
In the CD4 <200 cells/mm3 population (Table 4, Figure 1;
narrower CD4 subgroups in Appendix Table A9), standard-
prophylaxis (Strategy-1) was the least costly and least effec-
tive strategy. Enhanced-prophylaxis (Strategy-2) was the third
least costly, and also the most effective strategy, with an ICER
of US$157/QALY versus standard-prophylaxis (with standard-
prophylaxis plus fluconazole extendedly dominated).
Enhanced-prophylaxis was more effective and less costly than
all CrAg testing strategies (Strategies 4-6). At cost-effective-
ness thresholds of US$300 and US$500, enhanced-prophy-
laxis is cost-effective, with probability of not being cost-
effective of only 22% and 8% respectively; the incremental
net health benefits per 1000 individuals are 9.91 and 14.26
QALYs respectively.
Results were similar in the CD4 <100 cells/mm3 population
(Table 4, Figure 1), with standard-prophylaxis being the least
costly and least effective strategy, and enhanced-prophylaxis
the third least costly, but most effective. Given higher mortal-
ity in this more advanced population, the ICER for enhanced-
prophylaxis versus standard-prophylaxis was lower at US
Table 3. Breakdown of treatment effects by strategy
Cryptococcal disease
(mortality & hospitalizations) Other hospitalizations Deaths unknown causes
Effect in EP versus SP assumed due to Fluconazole Isoniazid, azithromycin
and albendazole
Isoniazid, azithromycin
and albendazole
No CrAg testing
Strategy-1: SP
Strategy-2: EP X X X
Strategy-3: SPplusF X
CrAg testing
Strategy-4: CrAg EP+ve SP−ve X if CrAg-positive X if CrAg-positive X if CrAg-positive
Strategy-5: CrAg EP+ve EPlessF−ve X if CrAg-positive X X
Strategy-6: CrAg SPplusF+ve SP−ve X if CrAg-positive
X – receive treatment effect based on EP versus SP.
+ve, a positive CrAg test; −ve, a negative CrAg test; CrAg, cryptococcal antigen; EP, enhanced-prophylaxis; EPlessF, enhanced-prophylaxis less flu-
conazole; SP, standard-prophylaxis; SPplusF, standard-prophylaxis plus fluconazole.
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$113/QALY; therefore enhanced-prophylaxis remains cost-
effective at the two higher cost-effectiveness thresholds with
lower decision uncertainty.
Considering all individuals presenting with HIV, regardless
of CD4 count (Table 4, Figure 1), the ICER for enhanced-
prophylaxis versus standard-prophylaxis was US$722/QALY,
indicating that it is not cost-effective at any of the cost-effec-
tiveness thresholds considered.
The largest cost-savings from enhanced-prophylaxis relate
to hospitalizations, and are not markedly different for clinic
Table 4. Base-case cost-effectiveness results
CD4 <200 cells/mm3 Costs (US$)
QALY
(max 0.923)
LY
(max 0.923)
Incremental net health benefit
(probability of being cost-effective), QALY
Incremental
cost-effectiveness
ratios
K = $100 K = $300 K = $500 Cost per QALY
Strategy-1: SP $122.84 0.81015 0.85028 – (0.835) – (0.217) – (0.077) –
Strategy-3: SPplusF $125.11 0.81408 0.85409 −0.01881 (0) −0.00366 (0) −0.00062 (0.001) Ext dominated
Strategy-2: EP $126.10 0.83095 0.86451 −0.01186 (0.165) 0.00991 (0.783) 0.01426 (0.922) $157.01
Strategy-6: CrAg
SPplusF+ve SP−ve
$128.49 0.81319 0.85323 −0.05346 (0) −0.0158 (0) −0.00826 (0) Dominated
Strategy-4: CrAg
EP+ve SP−ve
$128.58 0.81438 0.85405 −0.05324 (0) −0.01493 (0) −0.00727 (0) Dominated
Strategy-5: CrAg
EP+ve EPlessF−ve
$129.28 0.83004 0.86363 −0.04451 (0) −0.00158 (0) 0.00701 (0) Dominated
CD4 <100 cells/mm3
Strategy-1: SP $122.83 0.78407 0.81875 – (0.677) – (0.021) – (0.005) –
Strategy-3: SPplusF $124.94 0.79120 0.82568 −0.01396 (0) 0.0001 (0.001) 0.00292 (0.002) Ext dominated
Strategy-2: EP $126.13 0.81339 0.84140 −0.00368 (0.322) 0.01832 (0.979) 0.02272 (0.993) $112.53
Strategy-6: CrAg
SPplusF+ve SP−ve
$128.40 0.78974 0.82427 −0.05007 (0) −0.01291 (0) −0.00548 (0) Dominated
Strategy-4: CrAg
EP+ve SP−ve
$128.56 0.79177 0.82573 −0.04959 (0) −0.01139 (0) −0.00376 (0) Dominated
Strategy-5: CrAg
EP+ve EPlessF−ve
$129.39 0.81188 0.83994 −0.03781 (0) 0.00593 (0) 0.01468 (0) Dominated
All individuals with HIVa
Strategy-1: SP $44.93 0.88708 0.90027 – – – –
Strategy-3: SPplusF $47.41 0.88821 0.90137 −0.02369 −0.00714 −0.00383 Ext dominated
Strategy-2: EP $49.65 0.89361 0.90464 −0.04067 −0.00920 −0.00291 $722.27
Strategy-6: CrAg
SPplusF+ve SP−ve
$50.58 0.88799 0.90116 −0.05558 −0.01792 −0.01038 Dominated
Strategy-4: CrAg
EP+ve SP−ve
$50.61 0.88838 0.90143 −0.05552 −0.01764 −0.01006 Dominated
Strategy-5: CrAg
EP+ve EPlessF−ve
$52.75 0.89339 0.90443 −0.07191 −0.01976 −0.00933 Dominated
CrAg, cryptococcal antigen; EP, enhanced-prophylaxis; EPlessF, enhanced-prophylaxis less fluconazole; Ext dominated, extendedly dominated;
K, cost-effectiveness threshold; LY, life years; QALY, quality adjusted life years; SP, standard-prophylaxis; SPplusF, standard-prophylaxis plus
fluconazole.
a
In patients with CD4 >200 cell/mm3, only costs of the prophylaxis and CrAg testing are included.
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Figure 1. Cost-effectiveness planes. EP, enhanced-prophylaxis; EPlessF, enhanced-prophylaxis less fluconazole; ICER, incremental cost-effec-
tiveness ratio; QAYL, quality-adjusted life-years; SP, standard prophylaxis; SPplusF, standard prophylaxis plus fluconazole.
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visits or other (non-prophylaxis) drug costs (Appendix Fig-
ure A3).
3.3 | Scenario analyses
Scenario analyses in the CD4 <200 cells/mm3 population
(Table 5, other populations in Appendix Tables A10-A12)
show results are sensitive to the substantial between-country
differences in drug prices (Table 2). For Kenyan or Ugandan
prices, results are similar to the base-case but with higher
ICERs for enhanced-prophylaxis, US$229 and US$353/QALY
respectively. For Malawian or Zimbabwean prices, results
change as enhanced-prophylaxis becomes the most expensive
strategy, due to high local fluconazole and azithromycin costs
respectively. Enhanced-prophylaxis and the second CrAg test-
ing strategy (no longer dominated in this scenario) present
ICERs above all thresholds considered, hence standard-pro-
phylaxis is cost-effective. Other scenarios are similar to the
base-case but with different ICERs for enhanced-prophylaxis:
US$178/QALY for FDC costing US$12 per year; US$292/
QALY for 200 mg fluconazole prophylaxis; US$185/QALY
truncating HRQoL at 0.9; and US$162/QALY for alternative
model for cryptococcal meningitis mortality. Considering
WHO-recommended pre-emptive fluconazole treatment in
CrAg-positive individuals, the second CrAg strategy was the
most effective but also the most costly, with an ICER of US
$4,509/QALY. The impact of the scenarios was broadly similar
across the different populations, with results most sensitive to
drug prices, and the cost-effectiveness of enhanced-prophy-
laxis more favourable in the most advanced population.
The maximum CrAg test prices that make a CrAg testing
strategy cost-effective are markedly lower than the base-case
value of US$5.66 (Appendix Figure A4); at a US$300/QALY
threshold, the maximum price should be US$2.26 in the CD4
<200 cells/mm3 population.
The maximum CD4 test price to stratify individuals to dif-
ferent strategies is US$2.21 at a threshold of US$500/QALY
(Appendix Figure A4).
4 | DISCUSSION
This study is the first to compare enhanced-prophylaxis pack-
ages for opportunistic infections with other prophylaxis strate-
gies, including CrAg-based targeted prophylaxis, for HIV-
positive individuals in sub-Saharan Africa. The full enhanced-
prophylaxis package (tested in REALITY) confers significant
health benefits and is cost-effective at accepted cost-effective-
ness thresholds providing constituent drugs are available at
cheapest prices in the four countries included in the REALITY
trial. The incremental cost of prophylaxis per patient was only
$5.46 versus standard care, which is offset by cost-savings
elsewhere. Enhanced-prophylaxis was more effective and less
costly than all CrAg testing strategies as the enhanced-pro-
phylaxis still conveyed health gains in CrAg-negative patients
and the savings from targeting prophylaxis based on CrAg sta-
tus do not compensate for the cost of CrAg testing.
The cost-effectiveness of enhanced-prophylaxis was, how-
ever, highly sensitive to drug component prices, which varied
widely by country. Using country specific costs, enhanced-pro-
phylaxis presented an ICER of US$230/QALY, US$353/QALY,
and US$501/QALY in Kenya, Uganda and Malawi respectively.
For enhanced-prophylaxis to be recommended in late presen-
ters, efforts are needed to minimize drug prices. Lessons
should be learned from international efforts to negotiate and
drive down prices of ART in sub-Saharan Africa [24].
Our analyses indicate that strategies involving CrAg testing,
as currently recommended by WHO guidelines for advanced
HIV disease, are not cost-effective at a CrAg test cost of US
$5.66, the actual cost for the test within the REALITY trial.
Sensitivity analysis indicate that, for the CD4 <200 cells/mm3
population, CrAg testing only becomes cost-effective (using a
cost-effectiveness threshold of US$300/QALY) at a much
lower cost of US$2.26 per test. Whilst the manufacturer
quotes test costs of USD$2.50, this does not include shipping
or labour. Other recent studies have estimated costs of USD
$3.41-$5.24 in Africa [25–27] while study partners have indi-
cated costs of USD$7-$10.
Our study also shows the value of stratifying individuals accord-
ing to pre-ART CD4 count, whose measurement has recently
been reported to greatly reduce mortality [28]. It is difficult to
identify individuals with advanced HIV via symptoms alone; for
example, all individuals in REALITY had CD4 <100 cells/mm3
(median 37 cells/mm3), but around half had few or no clinical
symptoms. Using enhanced-prophylaxis in all individuals at pre-
sentation is not cost-effective; CD4 tests must cost under US
$2.28 to be cost-effective if solely used for enhanced-prophylaxis
stratification (at the US$500/QALY threshold), considerably
below published CD4 prices [29]. However, CD4 testing also
identifies individuals at high risk of imminent morbidity/mortality
after restarting ART after interruption, or switching to second-line
ART, where enhanced-prophylaxis may also be valuable [11].
A previous study examining the cost-effectiveness of CrAg
screening to target prophylaxis in South Africa found the
CrAg screening strategies to be more effective and less costly
than universal fluconazole prophylaxis [30]. However, the uni-
versal prophylaxis considered was 200 mg daily for a year,
rather than 100 mg daily for 12 weeks as in REALITY, and
the cost of fluconazole was much higher than in REALITY
countries. The study also considered only cryptococcal mortal-
ity in CrAg-positive individuals (i.e. assumed no benefits of flu-
conazole in individuals testing CrAg-negative, despite the
potential for false-negatives and the possibility of infection
with cryptococcus shortly after ART initiation [14]). Additional
benefits from targeted pre-emptive treatment with higher flu-
conazole doses (as defined by WHO) were considered in our
scenario analysis and the additional cost was not value-for-
money even if it eliminated all cryptococcal mortality and hos-
pitalizations. Importantly, while not considered explicitly here,
enhanced-prophylaxis can be administered immediately to
individuals starting ART, whereas in some situations additional
CrAg testing may result in delays in ART initiation with likely
mortality in those at high risk awaiting test results.
The REMSTART trial investigated CrAg screening and commu-
nity-based early adherence support in individuals starting ART
with CD4 <200 cells/mm3, with CrAg-positive individuals receiv-
ing 10 weeks of fluconazole (at WHO recommended doses) in
Tanzania and Zambia. The trial found that CrAg screening and
adherence support was cost-effective versus standard care in
low-income settings [22,27]. However, this analysis did not con-
sider alternative prophylaxis strategies and importantly did not
separate benefits of CrAg screening from adherence support in
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Table 5. Scenario analyses for the CD4 <200 cells/mm3 population
CD4 <200 cells/mm3 Costs (US$) QALY LY
Incremental net health benefit
Incremental
cost-effectiveness
ratios
K = $100 K = $300 K = $500 Cost per QALY
Country-specific drug costs
Strategy-1: SP $126.10 0.81361 0.85371
Strategy-6: CrAg SPplusF+ve SP−ve $132.04 0.81640 0.85643 −0.05662 −0.01701 −0.00909 Ext dominated
Strategy-4: CrAg EP+ve SP−ve $132.69 0.81757 0.85722 −0.06198 −0.01802 −0.00922 Ext dominated
Strategy-3: SPplusF $133.50 0.81706 0.85707 −0.07051 −0.02121 −0.01134 Dominated
Strategy-5: CrAg EP+ve EPlessF−ve $142.05 0.83281 0.86635 −0.14034 −0.03398 −0.01271 $830.99
Strategy-2: EP $143.90 0.83349 0.86701 −0.10153 −0.02245 −0.00664 $2,726.13
Zimbabwe-specific drug costs
Strategy-1: SP $124.87 0.81361 0.85371
Strategy-6: CrAg SPplusF+ve SP−ve $130.76 0.81640 0.85643 −0.05603 −0.01682 −0.00898 Ext dominated
Strategy-3: SPplusF $131.34 0.81706 0.85707 −0.06126 −0.01812 −0.00949 Ext dominated
Strategy-4: CrAg EP+ve SP−ve $132.40 0.81757 0.85722 −0.07131 −0.02113 −0.01109 Ext dominated
Strategy-5: CrAg EP+ve EPlessF−ve $157.48 0.83281 0.86635 −0.30683 −0.08948 −0.04601 Ext dominated
Strategy-2: EP $158.61 0.83349 0.86701 −0.26151 −0.07578 −0.03863 $1,697.51
Uganda-specific drug costs
Strategy-1: SP $126.87 0.81361 0.85371
Strategy-3: SPplusF $130.49 0.81706 0.85707 −0.03282 −0.00864 −0.00381 Ext dominated
Strategy-6: CrAg SPplusF+ve SP−ve $132.59 0.81640 0.85643 −0.05445 −0.01629 −0.00866 Dominated
Strategy-4: CrAg EP+ve SP−ve $132.83 0.81757 0.85722 −0.05567 −0.01591 −0.00796 Ext dominated
Strategy-2: EP $133.88 0.83349 0.86701 −0.05022 −0.00349 0.00586 $352.65
Strategy-5: CrAg EP+ve EPlessF−ve $135.49 0.83281 0.86635 −0.03424 −0.00091 0.00576 Dominated
Malawi-specific drug costs
Strategy-1: SP $123.74 0.81361 0.85371
Strategy-6: CrAg SPplusF+ve SP−ve $130.71 0.81640 0.85643 −0.06691 −0.02044 −0.01115 Ext dominated
Strategy-4: CrAg EP+ve SP−ve $131.04 0.81757 0.85722 −0.06899 −0.02035 −0.01063 Ext dominated
Strategy-5: CrAg EP+ve EPlessF−ve $133.45 0.83281 0.86635 −0.07792 −0.01317 −0.00023 $505.87
Strategy-3: SPplusF $148.96 0.81706 0.85707 −0.24874 −0.08062 −0.04699 Dominated
Strategy-2: EP $153.81 0.83349 0.86701 −0.21385 −0.05989 −0.02910 $30,009.37
Kenya-specific drug costs
Strategy-1: SP $126.42 0.81361 0.85371
Strategy-3: SPplusF $128.68 0.81706 0.85707 −0.01906 −0.00406 −0.00106 Ext dominated
Strategy-2: EP $130.98 0.83349 0.86701 −0.02564 0.00470 0.01077 $229.00
Strategy-6: CrAg SPplusF+ve SP−ve $132.07 0.81640 0.85643 −0.05364 −0.01602 −0.00850 Dominated
Strategy-4: CrAg EP+ve SP−ve $132.24 0.81757 0.85722 −0.05422 −0.01543 −0.00767 Dominated
Strategy-5: CrAg EP+ve EPlessF−ve $134.17 0.83281 0.86635 −0.03917 −0.00255 0.00477 Dominated
FDC costs $12 per year
Strategy-1: SP $123.76 0.81361 0.85371
Strategy-3: SPplusF $125.12 0.81706 0.85707 −0.01017 −0.00109 0.00072 Ext dominated
Strategy-2: EP $127.31 0.83349 0.86701 −0.01559 0.00806 0.01278 $178.41
Strategy-6: CrAg SPplusF+ve SP−ve $129.34 0.81640 0.85643 −0.05304 −0.01582 −0.00838 Dominated
Strategy-4: CrAg EP+ve SP−ve $129.51 0.81757 0.85722 −0.05353 −0.01520 −0.00753 Dominated
Strategy-5: CrAg EP+ve EPlessF−ve $130.50 0.83281 0.86635 −0.03803 −0.00217 0.00500 Dominated
200 mg fluconazole dosage
Strategy-1: SP $122.89 0.81361 0.85371
Strategy-3: SPplusF $127.54 0.81706 0.85707 −0.04311 −0.01207 −0.00587 Ext dominated
Strategy-6: CrAg SPplusF+ve SP−ve $128.66 0.81640 0.85643 −0.05492 −0.01645 −0.00875 Dominated
Strategy-2: EP $128.68 0.83349 0.86701 −0.03807 0.00056 0.00829 $291.55
Strategy-4: CrAg EP+ve SP−ve $128.76 0.81757 0.85722 −0.05481 −0.01563 −0.00779 Dominated
Strategy-5: CrAg EP+ve EPlessF−ve $129.45 0.83281 0.86635 −0.00332 0.00940 0.01194 Dominated
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the intervention arm. A recent modelling study for Botswana
found reflexive CrAg screening of individuals with CD4
<100 cells/mm3 and treatment of identified CrAg-positives was
cost-effective with an incremental cost of US$2 per DALY
averted versus no screening. [25] However, this study did not
consider a universal prophylaxis strategy in populations with low
CD4. Similarly, studies of national CrAg screening programmes in
individuals with HIV in Uganda and Vietnam found they were a
cost-effective use of resources versus not screening [26,31], but
again did not consider a universal prophylaxis strategy and
focussed on screening the whole HIV population, rather than
those presenting with advanced HIV in whom we found universal
prophylaxis to be cost-effective.
Study strengths include the use of the best available data
to assess the cost-effectiveness of different prophylaxis strate-
gies based on the REALITY trial package and CrAg screening,
including factor-specific models based on extensive detailed
data collected in the trial. The model closely fits REALITY sur-
vival data suggesting good internal validity. Using a decision-
analytic modelling approach enabled us to consider cost-effec-
tiveness in individuals with CD4 100-200 cells/mm3. Uncer-
tainty in model parameters was reflected using probabilistic
sensitivity analysis, and the impact on results of key uncertain-
ties was quantified using scenario analysis.
Limitations include the fact that factors such as improved
adherence in the trial may affect generalizability. However,
comparisons between randomized groups (on which cost-ef-
fectiveness is based) are not affected by this and higher
underlying mortality rates outside of a trial would mean our
results are conservative regarding benefits from enhanced-
prophylaxis. Some of our strategies were not considered
directly in the trial, and analyses hence required assumptions
about the impact of the individual package components on dif-
ferent reasons for mortality and hospitalization (these are
highlighted in Table 3). Modelling cost-effectiveness in sub-
groups not included in the REALITY trial (i.e. individuals with
CD4 >100 cells/mm3) involved extrapolating relationships
between CD4 and cause-specific mortality hazards, costs and
HRQoL. The trial, and our analyses, only considered 100 mg
fluconazole daily prophylaxis; higher doses might have higher
efficacy in CrAg-positive individuals [32], although the lower
REALITY dose reduced cryptococcal mortality. Our scenario
analysis showed that even if higher pre-emptive treatment
doses eliminated all cryptococcal mortality and hospitaliza-
tions, it would not be cost-effective at accepted thresholds.
Another limitation is that hospitalization costs were obtained
from WHO CHOICE and do not distinguish by reason for
hospitalization or capture all treatments or diagnostic tests
received, although drug costs would have been included as
concomitant medications. This will underestimate cryptococcal
hospitalization costs, which means our analyses will be conser-
vative towards the extended-prophylaxis regime.
Table -0005. (Continued)
CD4 <200 cells/mm3 Costs (US$) QALY LY
Incremental net health benefit
Incremental
cost-effectiveness
ratios
K = $100 K = $300 K = $500 Cost per QALY
Full-health EQ-5D score 0.9
Strategy-1: SP $122.89 0.74263 0.85371
Strategy-3: SPplusF $125.12 0.74573 0.85707 −0.01925 −0.00435 −0.00137 Ext dominated
Strategy-2: EP $126.10 0.76002 0.86701 −0.01478 0.00667 0.01096 $184.95
Strategy-6: CrAg SPplusF+ve SP−ve $128.52 0.74514 0.85643 −0.05379 −0.01626 −0.00875 Dominated
Strategy-4: CrAg EP+ve SP−ve $128.61 0.74617 0.85722 −0.05373 −0.01555 −0.00792 Dominated
Strategy-5: CrAg EP+ve EPlessF−ve $129.30 0.75941 0.86635 −0.02808 −0.00024 0.00533 Dominated
Alternate specification for CM survival
Strategy-1: SP $122.89 0.81363 0.85373
Strategy-3: SPplusF $125.12 0.81705 0.85706 −0.01888 −0.00401 −0.00104 Ext dominated
Strategy-2: EP $126.10 0.83348 0.86700 −0.01228 0.00914 0.01343 $161.85
Strategy-6: CrAg SPplusF+ve SP−ve $128.54 0.81664 0.85666 −0.05353 −0.01584 −0.00830 Dominated
Strategy-4: CrAg EP+ve SP−ve $128.64 0.81782 0.85746 −0.05333 −0.01498 −0.00731 Dominated
Strategy-5: CrAg EP+ve EPlessF−ve $129.33 0.83306 0.86659 −0.02606 0.00199 0.00760 Dominated
WHO pre-emptive therapy|CrAg+ve
Strategy-1: SP $122.89 0.81361 0.85371
Strategy-2: EP $126.10 0.83349 0.86701 −0.01230 0.00915 0.01344 $161.88
CrAg SP & WHO+ve SP−ve $128.61 0.81794 0.85791 −0.05289 −0.01475 −0.00712 Dominated
Strategy-4: CrAg EP+ve SP−ve $128.61 0.81757 0.85722 −0.05331 −0.01513 −0.00749 Dominated
CrAg EP & WHO+ve SP−ve $128.63 0.81896 0.85856 −0.05205 −0.01378 −0.00613 Dominated
CrAg EP & WHO+ve EPlessF−ve $129.31 0.83420 0.86769 −0.04366 −0.00083 0.00774 $4,509.19
CrAg, cryptococcal antigen; EP, enhanced-prophylaxis; EPlessF, enhanced-prophylaxis less fluconazole; Ext dominated, extendedly dominated; FDC,
fixed dose combination; K, cost-effectiveness threshold; LY, life years; QALY, quality adjusted life years; SP, standard-prophylaxis; SPplusF, stan-
dard-prophylaxis plus fluconazole; WHO, World Health Organization recommended fluconazole regimen.
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Some potential benefits of prophylaxis are not included in
the model, for example, reductions in oral and oesophageal
candida with fluconazole, which impacts HRQoL, and the con-
sequences of any delays in ART initiation while waiting for
CrAg test results (recognized in WHO 2018 cryptococcal
guidelines [33] which state that “fluconazole primary prophy-
laxis should be made available in settings in which CrAg
screening is not available or there may be prolonged delays in
receiving the result”). Both make the current analysis conser-
vative with respect to enhanced-prophylaxis.
Our analyses did not include effects of teratogenicity
because fluconazole is classed as Category D only for
doses ≥ 400 mg daily; assuming that no pregnant woman
would start fluconazole under universal or targeted strategies,
the probability of new pregnancy in 12 weeks is low, at least
in the advanced population. Finally, the model only estimated
results over 48 weeks, reflecting trial follow-up. Absolute mor-
tality benefits with enhanced-prophylaxis versus standard-pro-
phylaxis are likely to persist much longer.
5 | CONCLUSIONS
In conclusion, the REALITY enhanced-prophylaxis package in
individuals initiating ART with CD4 <200 cells/mm3 confers
significant benefit to individuals and appears cost-effective at
accepted cost-effectiveness thresholds. Efforts should con-
tinue to ensure that the components of the package can be
accessed at lowest available prices.
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